Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00341419 · ClinicalTrials.gov registry record
Genetic Analysis of Patients With Pseudoxanthoma Elasticum
A clinical trial of Pseudoxanthoma Elasticum and PXE, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 188
- Enrollment target
- 1
- Study location
NCT00341419: Completed study of Pseudoxanthoma Elasticum and PXE, sponsored by National Cancer Institute (NCI).
NCT00341419 is a study of Pseudoxanthoma Elasticum and PXE that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 188 participants, above the 94-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (100% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00341419, a study of Pseudoxanthoma Elasticum and PXE, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 188 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will characterize the gene mutations responsible for pseudoxanthoma elasticum (PXE) and correlate them with disease manifestations in males and females. PXE is an inherited disorder that affects the connective tissue in some parts of the body. Calcium and other minerals are deposited in the connective tissue, causing changes in the skin, eyes, cardiovascular system and gastrointestinal system. Some effects of PXE can cause serious medical problems, while others have less impact. Symptoms often appear earlier and are more severe in females than in males, but there is no way to predict how the disorder will progress in any given individual. Candidates for this study are recruited through PXE International, an organization that provides patient support and supports research on the disease. The organization collects biological samples and medical information on patients and family members to help further research on the disease. Families that have samples from the patient, both parents, and at least one sibling may be eligible for this study. Grandparents and extended family members may be included in certain instances. Participants provide a blood sample, a sample of cells scraped from the inside of the cheek (buccal cells) and a medical history. The samples are analyzed for gene variants and the findings are correlated with disease signs and symptoms. ...
Conditions Studied
Study Locations (1)
Maryland
- National Cancer Institute (NCI), 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 188 participants |
| Start Date | 2005-02-16 |
| Est. Completion | 2013-05-14 |
What the finished NCT00341419 record still lists
NCT00341419 is an observational study that tracks outcomes without assigning an intervention. The registered 188 participants enrollment target is mid-sized for trials with a published cap, above the 94-participant average among 3 other Pseudoxanthoma Elasticum trials with a reported enrollment target (100% higher).
The record links to 2 conditions, with Pseudoxanthoma Elasticum appearing as the primary indexed condition, and to 0 interventions.
NCT00341419 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT00341419 about?
NCT00341419 is a clinical study titled "Genetic Analysis of Patients With Pseudoxanthoma Elasticum". This study will characterize the gene mutations responsible for pseudoxanthoma elasticum (PXE) and correlate them with disease manifestations in males and females. PXE is an inherited disorder that affects the connective tissue in some parts of the body. Calcium and other minerals are deposited in t...
What is the current status of trial NCT00341419?
This trial is currently completed. The enrollment target is 188 participants. The study started on 2005-02-16. Estimated completion is 2013-05-14.
What conditions does trial NCT00341419 study?
This clinical trial studies the following conditions: Pseudoxanthoma Elasticum, PXE.
Who is sponsoring clinical trial NCT00341419?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00341419 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pseudoxanthoma Elasticum
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 Deficiency
RECRUITING · Phase 1
-
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
RECRUITING · Phase 2
-
A Study of DS-1211b in Individuals With PseudoXanthoma Elasticum
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03422198 · 188 participants · Phase 3
Short Course Vaginal Cuff Brachytherapy in Treating Participants With Stage I-II Endometrial Cancer
- NCT04469790 · 188 participants · NA
Effects of Multi-day Interruptions in Sitting on Type 2 Diabetes-relevant Outcomes in Children
- NCT04671667 · 188 participants · Phase 2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- NCT04853251 · 188 participants · Phase 4
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI